Clinical trials
Ventricular Dysfunction, Left trials in the United States with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
19 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2007 | 2 |
| 2009 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 4 |
| 2024 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Active, not recruiting | 4 |
| Terminated | 3 |
| Not yet recruiting | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Abiomed Inc. | 2 |
| Abbott Medical Devices | 1 |
| BioVentrix | 1 |
| Boston Scientific Corporation | 1 |
| JenaValve Technology, Inc. | 1 |
| Pugazhendhi Vijayaraman | 1 |
| Sunnybrook Health Sciences Centre | 1 |
| Tulane University | 1 |
| University of Alabama at Birmingham | 1 |
| University of California, San Francisco | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ventricular Dysfunction, Left | 19 |
| Heart Failure | 6 |
| Coronary Artery Disease | 3 |
| Cardiovascular Diseases | 2 |
| Death, Sudden, Cardiac | 2 |
| Anterior Wall Myocardial Infarction | 1 |
| Aortic Valve Disease | 1 |
| Aortic Valve Insufficiency | 1 |
| Aortic Valve Stenosis | 1 |
| Arrhythmias, Cardiac | 1 |
Trials
Showing 1 to 19 of 19. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.